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Abstract
Objective: Conﬁrmatory testing of suspected primary aldosteronism (PA) requires an extensive
medication switch that can be difﬁcult for patients with severe complicated hypertension and/or
refractory hypokalemia. For this reason, we investigated the effect of chronic antihypertensive
medication on conﬁrmatory testing results. To allow the results to be interpreted, the reproducibility of
conﬁrmatory testing was also evaluated.
Design and methods: The study enrolled 114 individuals with suspected PA who underwent two
conﬁrmatory tests. The patients were divided into two groups. In Group A, both tests were performed
on the guidelines-recommended therapy, i.e. not interfering with the renin–angiotensin–aldosterone
system. In Group B, the ﬁrst test wasperformed on chronic therapywiththe exclusion of thiazides, loop
diuretics, and aldosterone antagonists; and the second test was performed on guidelines-recommended
therapy. Saline infusion, preceded by oral sodium loading, was used to suppress aldosterone secretion.
Results: Agreement in the interpretation of the two conﬁrmatory tests was observed in 84 and 66% of
patients in Groups A and B respectively. For all 20 individuals in Group A who ever had end-test serum
aldosterone levels R240 pmol/l, aldosterone was concordantly nonsuppressible during the other test.
Similarly, for all 16 individuals in Group B who had end-test serum aldosterone levels R240 pmol/l on
modiﬁed chronic therapy, aldosterone remained nonsuppressible with guidelines-recommended therapy.
Conclusion: Conﬁrmatory testing performed while the patient is on chronic therapy without diuretics and
aldosterone antagonists can conﬁrm the diagnosis of PA, provided serum aldosterone remains markedly
elevated at the end of saline infusion.
European Journal of Endocrinology 166 679–686
Introduction
Primary aldosteronism (PA) is not an infrequent form of
secondary arterial hypertension. The cardiovascular
consequences of this disorder go beyond blood pressure
elevation (1, 2). It is important to identify PA cases as
affected individuals can beneﬁt from speciﬁc medical or
surgicaltreatment.ThePAdiagnosticalgorithmconsists
of screening, conﬁrmation, and subtype differentiation.
The main obstacle when diagnosing PA is the need for
a medication switch before conﬁrmatory testing.
According to the current guidelines (3), only drugs
with minimal or no effects on the renin–angiotensin–
aldosterone system (RAAS) can be administered before
and during the conﬁrmatory testing.
However, the medication change as suggested by the
guidelines carries a risk of uncontrolled hypertension
and severe hypokalemia. For this reason, conﬁrmatory
testing is often contraindicated in individuals with
severe complicated hypertension or a history of
signiﬁcant hypokalemia.
Conversely, the effects of chronic antihypertensive
therapy on conﬁrmatory testing are not completely
understood, and it is not known whether an extensive
medication change is necessary in all patients referred
for conﬁrmatory testing.
These facts inspired us to investigate this aspect of the
PA diagnostic process. To interpret the effects of chronic
therapy on conﬁrmatory testing, we also evaluated the
reproducibility of conﬁrmatory testing performed under
the recommended conditions.
Oral sodium loading with subsequent saline infusion
was used to suppress aldosterone secretion. This simple
procedure can be performed on an outpatient basis.
Subjects and methods
Patients with suspected PA who were referred for
conﬁrmatory testing on the basis of screening results
were prospectively enrolled. The study was approved by
the Local Ethics Committee, and all participants
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viduals were examined according to the protocol
described below.
PA screening
The aldosterone-to-renin ratio (ARR) was used to
screen patients with possible PA. Before ARR testing,
no changes in the patients’ medications were required
except for withdrawal from any aldosterone antagonist
for at least 2 months. These drugs were not allowed
until the PA diagnostic procedures were completed.
Blood sampling for ARR was always performed in the
morning(between 0700 and 1000 h)when the patients
had been in the upright position for at least 30 min. To
calculate ARR, both serum aldosterone and plasma
renin concentrations were expressed in nanograms per
liter. On the basis of our observations in healthy
volunteers, ARRs O20 were considered abnormal (4).
Referral for conﬁrmatory testing resulted mainly from
repeatedly elevated ARR in screened patients. However,
testing was also indicated for selected hypertensive
individuals who presented with otherwise unexplained
hypokalemia or an adrenal adenoma.
Conﬁrmatory testing
Two conﬁrmatory tests were performed for all enrolled
patients. The patients were divided into two groups
(A and B) that differed in the medication the patients
were given before testing. The patients were allocated
into the study groups consecutively, i.e. after enrolment
in one group was completed, enrolment in the other
group was initiated. The investigators had no inﬂuence
on the allocation of the patients into the respective
groups.
Group A
For patients in Group A, both conﬁrmatory tests were
performed under identical RAAS-neutral conditions, i.e.
excludinganyantihypertensive therapy interfering with
RAAS. These drugs had to be stopped at least 2 weeks
before the ﬁrst test. When the risks of uncontrolled
blood pressure were considered high, the patients were
given doxazosin and/or verapamil. The suggested period
between the two tests was 2 weeks. No changes in the
antihypertensive medications were allowed during the
period between tests. All patients who required any
antihypertensive therapy adjustment before the second
suppression test were excluded from the ﬁnal analysis.
Group B
For patients in Group B, the ﬁrst conﬁrmatory test
was performed under minimally modiﬁed chronic
antihypertensive therapy. Excluding aldosterone
antagonists that were not allowed at any point in the
diagnostic process, thiazides and loop diuretics had to
be stopped at least 2 weeks before the test. In patients
with a history of severe hypokalemia, amiloride was
permitted at a dose not exceeding 15 mg/day.
The second conﬁrmatory test was performed with
the exclusion of any antihypertensive therapy poten-
tially interfering with the RAAS. These drugs had
to be discontinued at least 2 weeks before testing. The
only antihypertensive medications allowed were dox-
azosin and/or verapamil. The results of the second
conﬁrmatory test were used as the reference for clinical
decision-making.
In both study groups, oral potassium supple-
mentation was administered as needed at any time
during the conﬁrmatory testing.
Group A
57 patients
Group B
57 patients
Confirmatory test
Confirmatory test
Chronic antihypertensive therapy
with exclusion of diuretics
† for
at least two weeks
No or RAAS-neutral* antihypertensive
therapy for at least two weeks
No or RAAS-neutral* antihypertensive
therapy for at least two weeks
Two confirmatory
tests (identical)
Final analysis
51 patients
Final analysis
53 patients
Excluded from the study:
Excluded from the study:
Four patients who required adjustments
to their antihypertensive treatments
Four patients who had non-
suppressible plasma renin levels
at the end of saline infusion
Two patients who had non-suppressible
plasma renin levels at the end of saline
infusion
Figure 1 Study protocol. Flowchart
describes the study protocol in brief,
including the study procedures and the
patients excluded from the analysis.
*Denotes a therapy with no or minimal effect
on the RAAS, only doxazosin and/or ver-
apamil were allowed.
†Only amiloride was
permitted at a dose not exceeding
15 mg/day.
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according to the protocol that is routinely used in our
center.
Oral sodium loading preceded the i.v. administration
of normal saline, as a short-lasting infusion itself might
not be sufﬁcient to suppress renin and aldosterone
secretion.
The patients were advised to enhance their oral salt
intake after adjusting their medication before testing.
Three days before the saline infusion was administered,
oral salt intake was further increased byat least 6 g/day.
The day before the saline infusion, a 24-h urine sample
was collected to measure urinary sodium excretion.
Saline was always infused in the morning. After 2 h
of bed rest, 2 l of normal saline was infused over a 4-h
period. The patients remained in the supine position
until the end of the infusion, when blood samples were
taken for the estimations of plasma renin and serum
aldosterone.
The criteria for interpreting conﬁrmatory tests were
based on our observations in healthy volunteers (4) as
follows: patients who had plasma active renin levels
R7 ng/l at the end of any conﬁrmatory test
performed during RAAS-neutral therapy were
excluded from the ﬁnal analysis. The exclusion limit
reﬂects the 97.5 percentile of the values observed in
healthy volunteers who underwent the same diag-
nostic protocol. Serum aldosterone was considered
suppressible at levels %100 pmol/l at the end of the
saline infusion. This cutoff is routinely used in our
center. It was set arbitrarily between the 97.5
percentile of the values of healthy volunteers
(60 pmol/l) and the lowest cutoff mentioned in the
current guidelines (139 pmol/l).
Adrenal venous sampling
Adrenal venous sampling (AVS) was offered to all
patients who had nonsuppressible serum aldosterone at
the end of any suppression test performed during RAAS-
neutral therapy.
The AVS protocol used in our center has been
described in detail elsewhere (5). In brief, a continuous
cosyntropin infusion was given during the procedure.
The adrenal veins were sequentially cannulated.
Adrenal samples were considered adequate if the
cortisol concentration was at least ﬁvefold greater
than that of the inferior vena cava. Adrenalectomy was
recommended to patients whose cortisol-corrected
aldosterone concentration from the affected gland
was at least fourfold higher than that of the
contralateral side.
Laboratory measurement
For all collected blood samples, the material was
processed and frozen within 1 h after the blood was
taken. Plasma renin measurements were performed
using the Renin III Generation radioimmunometric
assay (CIS Bio International, Gif sur Yvette Cedex,
France). The method’s detection range was 2.7–
340 ng/l. When the estimated renin concentration
was below the assay’s lower limit of detection, the
renin concentration was considered the lowest detect-
able value, i.e. 2.7 ng/l. The observed intra-assay
coefﬁcients of variation (CV values) were 9.5 and
3.2% for renin concentrations of 7.6 and 347.3 ng/l
respectively. The observed interassay CV values were
11.9 and 5.2% for renin concentrations of 24.6 and
281 ng/l respectively.
Serum aldosterone concentrations were measured
using a commercially available RIA (Coat-A-Count
aldosterone; Siemens/DPC, Los Angeles, CA, USA).
The assay’s range was 30–3880 pmol/l. When the
estimated aldosterone concentrations were below the
lower detection limit, the samples were considered to
have the lowest detectable serum aldosterone concen-
tration, i.e. 30 pmol/l. The observed intra-assay CV
values were 10.2 and 4.31% for aldosterone concen-
trations of 160 and 550 pmol/l respectively. The
observed interassay CV values were 10.3 and 7.6% for
aldosterone concentrations of 155 and 1560 pmol/l
respectively.
To calculate ARRs, both aldosterone and renin
concentrations were expressed in nanograms per liter.
To convert aldosterone concentration to mass units, a
coefﬁcient of 0.361 ng/pmol was used.
Statistical analysis
MedCalc Software (version 11.6) was used for the
statistical analysis of the acquired data.
Table 1 Patients’ principle characteristics. The table shows the
data of patients who were enrolled in the analysis. Unless otherwise
stated, the data are expressed as medians (ranges). Group A
patients underwent two identical conﬁrmatory tests under RAAS-
neutral therapy, only doxazosin and/or verapamil were allowed.
Group B patients underwent two conﬁrmatory tests: the ﬁrst during
modiﬁed chronic antihypertensive therapy and the second during
RAAS-neutral therapy, only doxazosin and/or verapamil were
allowed.
Group A Group B
No. of patients
(women)
51 (8) 53 (10)
Age (years) 47 (21–68) 57 (35–72)
Systolic BP
(mmHg)
a
142 (100–196) 138 (110–220)
Diastolic BP
(mmHg)
a
86 (64–116) 82 (54–118)
No. of antihypertensive
drugs
a
4 (0–7) 4 (1–6)
Aldosterone-to-renin ratio
a,b 66.9 (16.3–176.5) 77.5 (18.9–162.8)
aData obtained during the screening for primary aldosteronism.
bTo calculate the aldosterone-to-renin ratio, both aldosterone and renin were
expressed in nanograms per liter.
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The study consecutively enrolled 114 patients with
suspected PA. The patients were divided into two
groups: Groups A and B. All of the patients were
examined according to the study protocol (Fig. 1).
Group A
Group A included 57 patients, all of whom underwent
two conﬁrmatory tests under RAAS-neutral therapy. Six
individuals were excluded from the ﬁnal analysis: in two
patients, plasma renin remained unsuppressed after one
of the two tests, and in four patients, the verapamil
and/or doxazosin dose was modiﬁed after the ﬁrst test.
The reasons for these medication changes were side
effects and/or inadequate blood pressure control.
The data of the remaining 51 patients were included
in the analysis. Patients’ characteristics are shown in
Table 1. The antihypertensive medications administered
during both tests are summarized in Table 2.
Figure 2A compares the serum aldosterone concen-
trations at the end of both conﬁrmatory tests performed
in Group A patients. The difference in aldosterone
concentrations ranged from 0 to 350 pmol/l (median:
50 pmol/l).
Detailed results of both conﬁrmatory tests in Group A
patients are displayed in Tables 3 and 4. Overall,
agreement in the interpretation of the two tests was
noted in 43 (84%) patients. The data from the eight
patients who exhibited discordant results are shown in
more detail in Table 5.
All 20 patients who had serum aldosterone concen-
trations R240 pmol/l at the end of either conﬁrmatory
test exhibited aldosterone nonsuppressibility at the end
of the other test.
AVS was performed in 31 patients in Group A.
Aldosterone secretion lateralization was observed in 15
individuals. All patients with proven aldosterone
secretion lateralization had consistently nonsuppressi-
ble aldosterone at the end of both tests. None of the ﬁve
patients who had discordant conﬁrmatory test results
and underwent AVS exhibited evidence of aldosterone
secretion lateralization.
Group B
Fifty-seven patients with suspected PA were enrolled in
Group B. All were examined according to the study
protocol. Four individuals were excluded because of
high plasma renin at the end of the second conﬁrmatory
test performed during RAAS-neutral therapy. The data
of 53 patients were included in the analysis. The
principal characteristics of these patients are shown in
Table 1. The antihypertensive medications given before
both tests are summarized in Tables 2 and 6.
Figure 2B compares the serum aldosterone concen-
trations at the end of both tests. The difference in
aldosterone concentrations ranged from 0 to
360 pmol/l (median: 70 pmol/l).
Table 2 Antihypertensive medications given during conﬁrmatory
tests performed after excluding drugs that interfere with the RAAS.
The data are expressed as numbers of patients or medians (ranges).
Group A patients underwent two identical conﬁrmatory tests under
RAAS-neutral therapy conditions, only doxazosin and/or verapamil
wereallowed.GroupBpatientsunderwenttwoconﬁrmatorytests:the
ﬁrst with modiﬁed chronic antihypertensive therapy and the second
with RAAS-neutral therapy, only doxazosin and/or verapamil were
allowed.
Group A (51 patients) Group B (53 patients)
Number of
patients
Daily
dose (mg)
Number of
patients
Daily
dose (mg)
No therapy 5 9
Verapamil 46 240 (120–480) 44 240 (120–480)
Doxazosin 46 4 (1–16) 37 8 (2–16)
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y = –7.62 + 1.10 x
Intercept A 95% CI: –83.53–35.71
Slope B 95% CI: 0.86–1.44
y = 0.00 + 1.00 x
Intercept A 95% CI: –46.49–3.91
Slope B 95% CI: 0.87–1.20
Figure 2 Comparison of serum aldosterone at the end of the
conﬁrmatory tests. This graph compares the end-test serum
aldosterone (open circle) in Groups A (A) and B (B). Passing–
Bablok regression analysis was used to analyze the differences
between the compared conﬁrmatory tests. In both study groups,
wide 95% conﬁdence intervals (CI) describing the regression line
indicate only moderate agreement in the main results of the
compared conﬁrmatory tests. Bold lines indicate regression lines;
grey lines indicate 95% CI; and dotted lines indicate identity lines.
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Group B patients are summarized in Tables 3 and 7.
Consonant interpretations of conﬁrmatory tests were
noted in 35 (66%) patients, and discordant results were
found in 18 (34%) patients.
We have not identiﬁed any speciﬁc type of chronic
antihypertensive medication associated more frequently
with discordant results in the compared conﬁrmatory
tests.
Concerning amiloride administration, discordant
results were observed in four (20%) of 20 patients
who were given this drugas part of the modiﬁed chronic
therapy provided during the ﬁrst test.
All 16 individuals who had serum aldosterone levels
R240 pmol/l on modiﬁed chronic therapy end of
testing exhibited consonant results when the test was
repeated under RAAS-neutral therapy.
On the basis of the results of the second conﬁrmatory
test, 39 individuals underwent AVS. Aldosterone
secretion lateralization was observed in 14 patients,
three of these patients exhibited aldosterone suppression
during the conﬁrmatory test performed under modiﬁed
chronic antihypertensive therapy conditions.
Hypokalemia
Serum potassium was measured after oral sodium
loading before the saline infusion was given. Hypoka-
lemia, deﬁned as a potassium level !3.5 mmol/l, was
observed in 24 (23%) patients. All but one of these
patients received potassium supplementation, with a
mean dose of 46 (G18) mmol/day. No patient with
hypokalemia achieved aldosterone suppression at the
end of saline infusion.
Side effects
We did not encounter any major complications that
required acute hospital admission in any of the enrolled
patients.
Peripheral edema was observed in seven patients and
was more commonly associated with therapy limited to
verapamil and/or doxazosin. An episode of atrial
ﬁbrillation developed in one patient on doxazosin and
verapamil; hypokalemia was not detected. Dyspnea of
effort was reported by three patients, and two patients
reported headaches; neither complaint was related to
any speciﬁc therapy.
Discussion
Our study assessed the clinical value of conﬁrmatory
testing performed under modiﬁed chronic antihyper-
tensive therapy with the exclusion of thiazides, loop
diuretics, and aldosterone antagonists. To interpret the
results, the study protocol also evaluated the reprodu-
cibility of conﬁrmatory testing performed under RAAS-
neutral antihypertensive therapy conditions.
Table 3 Conﬁrmatory testing results. The data are expressed as medians and ranges. Group A patients underwent two identical
conﬁrmatory tests under RAAS-neutral therapy conditions. Group B patients underwent two conﬁrmatory tests: the ﬁrst with modiﬁed
chronic antihypertensive therapy and the second with RAAS-neutral therapy.
Group A (51 patients) Group B (53 patients)
Test 1
a,b Test 2
a,b Test 1
c Test 2
a
Aldosterone-to-renin ratio
d,e 45.7 (0.7–204.5) 47.0 (1.4–160.4) 61 (14–896) 62 (11–564)
Serum potassium level (mmol/l)
f 3.7 (2.7–4.6) 3.7 (2.9–4.7) 3.9 (2.7–4.8) 3.8 (2.6–4.7)
Urinary sodium excretion (mmol/24 h)
f 368 (124–814) 358 (142–721) 405 (60–776) 385 (90–704)
Plasma active renin after 2 h of bed rest (ng/l) 2.7 (2.7–10.8) 2.7 (2.7–7.4) 2.7 (2.7–38.8) 2.7 (2.7–43.2)
Serum aldosterone after 2 h of bed rest (pmol/l) 100 (30–1900) 160 (40–1880) 250 (50–1780) 255 (50–1230)
Plasma active renin at the end of saline infusion (ng/l) 2.7 (2.7–6.9) 2.7 (2.7–5.4) 2.7 (2.7–7.9) 2.7 (2.7–5.1)
Serum aldosterone at the end of saline infusion (pmol/l) 140 (30–2400) 160 (30–2020) 165 (40–1280) 165 (30–1330)
Systolic blood pressure (mmHg)
g 150 (120–192) 158 (116–196) 150 (118–220) 164 (115–218)
Diastolic blood pressure (mmHg)
g 92 (70–118) 94 (70–122) 90 (70–120) 95 (70–110)
aConﬁrmatory tests performed under RAAS-neutral therapy, only doxazosin and/or verapamil were allowed.
bConﬁrmatory tests performed with identical dosing of doxazosin and/or verapamil.
cConﬁrmatory tests performed under modiﬁed chronic antihypertensive therapy conditions, aldosterone antagonists and diuretics were withdrawn before
testing.
dBlood sampling was performed after oral sodium loading before the saline infusion was given.
eTo calculate the aldosterone-to-renin ratio, both aldosterone and renin were expressed in nanograms per liter.
fA 24-h urine sample was collected the day before the saline infusion was administered.
gBlood pressure measurement after saline infusion.
Table 4 The interpretation of conﬁrmatory tests in Group A
patients. The table compares the interpretation of two conﬁrmatory
tests in Group A patients. Both tests were performed under identical
conditions on RAAS-neutral therapy. The data are expressed as the
numbers of patients.
Serum aldosterone
at the end of saline
infusion
Test 1
Suppressible
(%100 pmol/l)
Nonsuppressible
(O100 pmol/l)
Test 2
Suppressible
(%100 pmol/l)
15 3
Nonsuppressible
(O100 pmol/l)
52 8
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testing performed with RAAS-neutral
antihypertensive therapy
Consonant results for two identical conﬁrmatory tests
were observed in a majority of examined patients;
however, the number of patients with discordant results
was not negligible. The only deﬁnite predictor of
concordantly positive results was the marked elevation
of serum aldosterone at the end of saline infusion.
We cannot provide any deﬁnite explanation for the
observed discrepancies. Some of the discordant ﬁndings
may result from imperfect renin suppression (in patients
2 and 7, Table 5) or insufﬁcient oral sodium loading
(patient 4, Table 5).
We suppose that autonomous aldosterone secretion
may be excluded in all patients who ever had serum
aldosterone suppression levels !60 pmol/l, i.e. below
the 97.5 percentile of values obtained from healthy
volunteers who underwent identical conﬁrmatory
testing (4).
The discrepant interpretations of the compared tests
cannot be attributed solely to the inherent imprecision
of laboratory methods. As is apparent from the data
presented in Table 5, the expected inaccuracies of
hormonal estimations were usually below the observed
differences in aldosterone concentrations.
We do not assume that previous chronic medical
therapy inﬂuenced the results. In all patients whose
data are presented in Table 5, the periods during which
they were not taking chronic medication were sufﬁcient
for the complete elimination of previously administered
antihypertensive medications.
We did not encounter hypokalemia ‘masking’ an
autonomous aldosterone secretion; the instances of
hypokalemia in our study resulted from excessive
aldosterone overproduction.
The effect of chronic antihypertensive
medication on the results of conﬁrmatory
testing
In one-third of Group B patients, there were discre-
pancies in the interpretation of the two conﬁrmatory
tests. Modiﬁed chronic medication was associated with
aldosterone suppressibility, even in a few of the patients
who were eventually found to have aldosterone
secretion lateralization.
Conversely, the highest end of the serum aldosterone
test with modiﬁed chronic therapy uniformly predicted
aldosterone nonsuppressibility when the test was
repeated under RAAS-neutral therapy. It appears that
severely excessive aldosterone overproduction may not
be effectively suppressed by modiﬁed chronic antihy-
pertensive medication.
It is also important to note that amiloride adminis-
tration did not inﬂuence the conﬁrmatory test results in
the majority of patients who received this drug as a part
Table 5 The analysis of data from Group A patients whose conﬁrmatory test results were discordant. Both tests were performed under the
same RAAS-neutral therapy conditions.
Test 1 Test 2
n
Days off
chronic
therapy
a
Urinary
sodium
(mmol/day)
b
Serum
potassium
(mmol/l)
c
Plasma
renin
(ng/l)
d
Serum
aldosterone
(pmol/l)
d
Urinary
sodium
(mmol/day)
b
Serum
potassium
(mmol/l)
c
Plasma
renin
(ng/l)
d
Serum
aldosterone
(pmol/l)
d
AVS/
lateralization
1 43 506 3.7 2.7 30 503 3.6 2.7 130 Yes/no
2 18 457 3.8 5.9 210 636 3.6 2.7 40 Yes/no
3 22 161 3.7 3 190 142 4.2 2.7 40 No/-
4 15 376 3.9 2.7 40 153 4.2 2.7 200 No/-
5 48 814 3.6 2.7 80 436 3.9 2.7 200 Yes/no
6 19 359 4.5 2.7 60 300 4.2 2.7 110 No/-
7 31 586 4.2 4.6 140 502 3.6 3.2 90 Yes/no
8 132 651 4.5 2.7 90 719 4.3 2.7 160 Yes/no
n, number of patients; -, indicates not applicable.
aNumber of days that chronic antihypertensive therapy with a potential inﬂuence on RAAS had been stopped before the ﬁrst conﬁrmatory test was performed.
The only drugs allowed during this period were doxazosin and verapamil.
bA 24-h urine sample was collected after oral sodium loading the day before the saline infusion was given.
cBlood sampling was performed after 3 days of oral sodium loading before the saline infusion was given.
dBlood samples were taken at the end of saline infusion. AVS denotes successful adrenal venous sampling. Lateralization denotes the lateralization of
aldosterone secretion from one adrenal gland.
Table 6 The modiﬁed chronic antihypertensive therapy adminis-
tered to Group B patients during the ﬁrst conﬁrmatory test. The data
are expressed as numbers of patients (percentages).
Beta blockers 45 (85%)
Angiotensin-converting enzyme inhibitors 35 (66%)
Angiotensin receptor blockers 8 (15%)
Calcium channel blockers 41 (77%)
Alpha blockers 31 (58%)
Centrally acting drugs 8 (15%)
Amiloride
a 20 (38%)
aThe mean dose of amiloride was 9 (G3.8) mg.
684 M Solar and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166
www.eje-online.orgof their modiﬁed chronic therapy. This observation may
be important for patients with severe hypokalemia, for
whom there are concerns about the safetyof performing
conﬁrmatory testing according to the therapy rec-
ommended by the guidelines.
Study limitations
The main limitation of our study is the unclear
deﬁnition of aldosterone suppressibility. There is no
gold standard for reliably conﬁrming autonomous
aldosterone production. Our study, as well as other
reports (6, 7, 8, 9, 10), used an arbitrary criterion to
deﬁne aldosterone suppressibility. Despite the fact that
our cutoff for deﬁning PA was rather low, we cannot be
sure that it was sufﬁcient to identify all individuals with
autonomous aldosterone secretion.
We are aware that the addition of one more
conﬁrmatory test to the study protocol would further
improve our understanding of the clinical question
studied. However, the extension of the study procedures
was considered highly impractical from the patients’
point of view.
Finally, our observations cannot be automatically
extrapolated as the reported data are closely related to
the protocol and the hormonal assays used. Signiﬁcant
differences among kits from different manufacturers
exist (11).
Conclusion
Our data suggest that an extensive medication switch is
not necessary for all patients who are referred for
conﬁrmatory testing for suspected PA. Chronic therapy
with the exclusion of aldosterone antagonists, thiazides,
and loop diuretics may offer an alternative to RAAS-
neutral therapy in patients with severe, complicated
hypertension and/or refractory hypokalemia.
The results of conﬁrmatory testing performed with
modiﬁed chronic therapyare valid only when the serum
aldosterone is markedly elevated at the end of saline
infusion. In the remaining cases, tests conducted under
modiﬁed chronic therapyconditions must be considered
inconclusive.
Another important ﬁnding of our study is the limited
reproducibility of conﬁrmatory testing under RAAS-
neutral therapy conditions. The conﬁrmatory test is
worth repeating unless the serum aldosterone concen-
tration is markedly high or markedly low at the end of
the test. The aim of repeated testing is to ﬁnd patients
who are able to suppress serum aldosterone to very low
levels, which makes a PA diagnosis improbable. The
need for AVS can be decreased by this approach.
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